Re: Blinded Sub Group Data; post by Aureus on IV

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Blinded Sub Group Data; post by Aureus on IV

in response to

Blinded Sub Group Data; post by Aureus on IV

BearDownAZ

posted on Oct 04, 2018 01:20PM

Re-posting a link to a previous post of mine detailing BETonMACE pre-specified sub-group analyses for the primary 3-point MACE outcome, and the various secondary outcomes. It is much more involved than just cognition and renal sub-groups.

Of particular interest to me is the rosuvastatin vs. atorvastatin pre-specified comparison for the primary 3-point MACE outcome. Recall in the Sept 2013 news release that further analysis of ASSURE found that patients treated with apabetalone beneficially synergized with rosuvastatin top provide tremendously greater plaque reduction than in patients treated with apabetalone plus atorvastatin, especially in those with below median HDL (all patients in BETonMACE will be low-HDL). You can see the data for yourself in this patent.